Algotec Research and Development Limited is a UK based company engaged in the development, manufacture and commercialisation of medical devices, with over 15 years of experience in the field of neuromodulation.
Algotec is the innovator of the unique NeuroStimulator PENS therapy technology which has successfully treated thousands of patients across the UK, Ireland, Europe and Australia suffering from chronic neuropathic pain to date. PENS therapy is a minimally invasive form of neuromodulation that provides patients with a safe and effective pain management option. The simplicity of PENS therapy increases accessibility to the benefits of neuromodulation for patients worldwide, by reducing risk and economic impact.
Algotech Research and Development SA (Pty) Limited was founded in 2010 to focus on the engineering of our R&D initiatives, while Algotec Research and Development UK remains focussed on international marketing. The all-female companies strive towards a global presence as innovators and manufacturers of medical devices, dedicated to improving the quality of patient care through therapies that address un-met needs with reduced risk, superior clinical results and economic value. Following a successful audit in March 2015 by the London office of Lloyd's Register Quality Assurance (LRQA), Algotech Research and Development SA is now formally certified against ISO 13485 and ISO 9001, making it not only one of a very elite group of certified medical device manufacturing companies in South Africa, but also the only all-female certified medical device manufacturing company in the world.
Our formal quality management system was first implemented in 2009 and has served as a solid foundation for sustained improvement and growth.